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Injectable Ketorolac and Corticosteroid
Use in Athletes: A Systematic Review
Timothy R. Jelsema, MD,† Anthony C. Tam, MD,† and James L. Moeller, MD*†
Context: The use of injectable medications to help athletes quickly return to the field of play after injury is common.
Understanding the effects and risks of these medications will help providers make informed decisions regarding their use in
this patient population.
Objective: To evaluate the utilization, efficacy, and adverse effects of injectable ketorolac and corticosteroids in athletes.
Data Sources: This systematic review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) guidelines. A systematic search of the literature was performed using multiple databases (PubMed, Embase,
Cochrane, Web of Science, and ClinicalTrials.gov). Secondary references were appraised for relevant articles. No randomized
controlled trials or other prospective studies were identified. Articles included retrospective database reviews and physician
survey studies.
Study Selection: A total of 6 studies met the inclusion and exclusion criteria and were reviewed by 2 independent
reviewers with a third consulted in the case of disagreement, which was not needed.
Study Design: Systematic review.
Level of Evidence: Level 5.
Data Extraction: Two reviewers recorded rate of use, effectiveness of treatment, and reported side effect data.
Results: Most studies centered around the football athlete, either professional or collegiate. Professional football game
day use of intramuscular ketorolac declined from 93.3% (28/30) in 2002 to 48% in 2016. Collegiate football game day use
of intramuscular ketorolac declined from 62% in 2008 to 26% in 2016. Game day corticosteroid injection was far lower than
ketorolac usage. Both medications were reported to be effective with few adverse events.
Conclusion: Use of injectable ketorolac is common but declining in professional and college football. Pain control efficacy
is good, and risk of adverse events is low. The incidence of injectable corticosteroid use in athletes is unknown. Use of
injectable corticosteroids in athletes allows for early return to sport activities with no reported complications.
Keywords: injection; ketorolac; corticosteroids; athlete
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usculoskeletal injuries account for a significant pain
burden worldwide. The World Health Organization
ranks musculoskeletal injuries as the number one
cause for long-term pain.2 In sport, musculoskeletal pain can
vary widely among athletes, resulting in moments of inaction or
entire games missed. Musculoskeletal injuries specific to muscle
fibers are often less severe, but chronic, and can be prone to
reinjury when inadequately managed. Ekstrand et al9 found that
muscle-specific injuries, strains, and contusions accounted for
nearly one-third of all injuries experienced in professional
soccer players over 8 years. Over 92% of those injuries were

confined to the lower limb, many of which were classified as
reinjury or aggravation of a nonhealed injury.9
A major problem faced by today’s team physician is managing
muscular injuries and associated pain. Multiple treatment
modalities are available, but the efficacy of each has been
questioned. The most common modalities utilized for pain
management include a combination of PRICE (protection, rest,
ice, compression, elevation), oral nonsteroidal antiinflammatories (NSAIDs), oral corticosteroids, intramuscular
(IM) injections for general pain relief, and corticosteroids
injected directly into the injured tissue. All modalities available
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Figure 1. Breakdown of cell membrane phospholipids
through the lipoxygenase and cyclooxygenase pathways,
leading to pain and inflammation.

to the sports physician attempt to address the natural response
of the body when dealing with an injury, with the goal of
returning the athlete to full participation in the least amount of
time and with the lowest risk for reinjury.
When muscle is injured, damage extends to the cellular level
and cell membranes lyse, spilling their contents into the local
tissue and bloodstream, initiating the inflammatory cascade.
Phospholipids from lysed cellular membranes are broken down
to arachidonic acid (AA), the primary building block of all
inflammatory biomarkers (Figure 1). AA is broken down via
either the lipoxygenase pathway or the cyclooxygenase (COX)
pathway. The former pathway leads to the production of
leukotrienes, compounds that act locally to increase vascular
2

permeability and facilitate chemotaxis of leukocytes to the area
of injury. The COX pathway is further differentiated into 2
pathways: COX-1 and COX-2. COX-1 is a constitutional pathway
that is always active in certain organ systems. COX-1 is
responsible for mucous production in the gut, temperature
maintenance in homeostasis, and preservation of kidney
function by maintaining dilation of the afferent arterioles in the
nephron. COX-2 is inducible and the primary target for pain
management for the physician. The COX-2 pathway produces
prostaglandins, prostacyclin, and thromboxane, substrates that
further recruit inflammatory cells, increase vascular permeability,
sensitize local nociceptive fibers, and assist in clotting.
NSAIDs primarily function as inhibitors of the COX pathways.
Most NSAIDs indiscriminately block COX-1 and COX-2. By
inhibiting the COX pathways, they work to prevent pain and
inflammation by reducing prostaglandin sensitization of
peripheral nociceptors and reducing vascular permeability by
reducing prostacyclin production.20 The inflammatory response
to muscle injury, however, is a crucial component of healing
despite the associated pain and discomfort. The natural healing
process can take days to weeks and requires several
overlapping steps related to cellular migration, proliferation, and
tissue remodeling. Each step involves a highly coordinated
incursion of leukocytes that are recruited by the products of the
COX and lipoxygenase pathways. A single administration of IM
ketorolac in injured rat muscle was shown to reduce the
concentration of 277 proteins, 14 of which had previously been
documented as integral to muscle injury repair.1
Oral corticosteroids are considered the most powerful
anti-inflammatories in any physician’s toolkit.20 Oral and
injectable corticosteroids inhibit both the lipoxygenase and COX
pathways. They prevent leukocytes from adhering to vascular
structures, thus preventing the diapedesis that allows these
inflammatory cells to congregate at sites of injury. For many
years, sports physicians have used injectable corticosteroids to
help injured athletes return to the field of play quickly. The
World Anti-Doping Agency (WADA) has banned corticosteroid
use (IM, intravenous [IV], oral, or rectal) in competitive play,
unless a Therapeutic Use Exemption (TUE) form is provided by
a physician noting their necessity.4,35 In recent years, ketorolac
has become the sport physician’s injectable medication of choice
to help athletes return to the field after injury.
This systematic review aims to evaluate the utilization, efficacy,
and adverse effects of injectable ketorolac and corticosteroids in
athletes.

Methods
This systematic review followed the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
guidelines.17 A systematic search of the literature was performed
using PubMed, Embase, Cochrane, and Web of Science
databases for studies published between January 1, 2000, and
October 16, 2019. A search for current studies using
ClinicalTrials.gov was also performed. The reference lists of any
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Figure 2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart of article assessment from
initial selection to final inclusion.

relevant systematic reviews and articles were manually checked
for relevant articles, and Google Scholar was utilized as a
secondary source. Keywords and Medical Subject Headings
terms were used separately and in combination in the search;
individually, these terms included injections OR inject, ketorolac
OR Toradol OR anti-inflammatory agent, non-steroidal OR
corticosteroid, AND athlete OR sport OR game OR athletic
injuries OR sports medicine. Articles were screened using
information from titles and abstracts, and the following
inclusion criteria were applied: published in English in a peerreviewed journal, was specific to the use of the injectable
medication (either ketorolac or corticosteroid) in athletes, and
presented new data on the topic. Studies were excluded if they
were review articles, animal studies, studies of chronic
musculoskeletal conditions, or studies of the general population.
No prospective studies were identified in the literature review.
With the identified studies being retrospective reviews of limited

patient populations and physician surveys, methodological
quality was rated as low. Studies were reviewed for data on
utilization, discussion of pain relief and ability to return to play
after injection, and discussion of adverse effects encountered
with the use of the injectable forms of ketorolac and
corticosteroids. Multiple forms of bias are possible in
retrospective reviews and physician surveys including collection
bias, observation bias, recall bias, and reporting bias.

Results
Of 8 articles identified,5,7,13,22,23,26,28,31 2 were excluded due to 1
being expert opinion22 and the other utilizing medications
other than ketorolac or corticosteroids.23 Thus, 6 studies met
the inclusion and exclusion criteria (Figure 2). When reviewing
individual studies for inclusion/exclusion, the 2 primary
reviewers were successful in achieving consensus, and no
3
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additional reviewer was needed. During screening of abstracts
and titles, the most common reasons for exclusion included
review article, chronic musculoskeletal condition, nonathlete
population, or medication other than ketorolac or
corticosteroid.
Study Characteristics
Identified studies were published between 2000 and 2018, with
4 physician surveys,5,26,28,31 1 retrospective review of a multiteam
injury database,13 and 1 retrospective review of medical records
from a single team.7 Five of the studies included only male
football athletes.5,7,13,28,31 One study included athletes from a
variety of sports and both male and female participants.26 Ages
were not specifically reported, but 4 studies included only
National Football League (NFL) athletes7,13,28,31 and 1 study only
collegiate athletes.5 A single survey study included questions
about athletes as young as 15 years old.26
Utilization of Injectable Ketorolac
and Corticosteroids in Athletes
There were no prospective reports on the use of injectable
ketorolac in athletes. In 2002, of 30 NFL teams responding to a
survey on game day use of ketorolac, 93.3% (28/30) reported
game day usage of IM ketorolac, with an average of 15 players
per team receiving an injection in the hours before kickoff.31
Most of the teams reported they would administer IM ketorolac
up to once a week for players during the season.31 A survey of
NFL head orthopaedic team physicians in 2008 showed that this
percentage was unchanged, and 79% of physicians would
administer 5 or more injections prior to each game.28 By 2016,
this number had dropped to 48% of physicians administering
game day ketorolac, with 28% administering 5 or more
injections per game.28 Utilization among National Collegiate
Athletic Association Division I football head orthopaedic team
physicians showed a similar decline, decreasing from 62% of
physicians reporting game day usage in 2008 to 26% in 2016.5 A
survey of the memberships of the American Medical Society for
Sports Medicine (AMSSM) and the American Orthopaedic
Society for Sports Medicine (AOSSM) in 2012 revealed that
nearly half of the 1100 responding physicians used IM ketorolac
in treatment of athletes.26 Nonsurgical sports medicine
physicians (AMSSM members) were more likely to use ketorolac
in general (orally or IM) compared with their surgical
counterparts and were also more likely to use IM ketorolac. Of
the physicians who used ketorolac, 79% used the medication in
the collegiate athlete population and 42.9% used it in the
professional athlete, and 53.7% of respondents listed 15 years
old as the minimum age at which they would consider pregame
ketorolac injection.26 Of respondents, 71% used injectable
ketorolac in both male and female athletes.26
There were also no prospective studies on the use of game
day corticosteroid injections in athletes, but the utilization of
game day corticosteroid injection appears to be far lower than
ketorolac usage. A retrospective review of 13 years of NFL data
reported only 58 corticosteroid injections directly into the injury
4

region of acute hamstring strain. The majority of these athletes
received their injection less than 72 hours after injury.13 A report
on the use of corticosteroid injection for a variety of muscle
strain and ligament sprain injuries in a single NFL team over a
period of 3 seasons revealed a total of 38 injections in 31
athletes.7
Effectiveness of Injectable Ketorolac
and Corticosteroids in Athletes
Effectiveness of injectable ketorolac and corticosteroids in
athletes was only reported in 4 studies.7,13,26,31 In 2000, most NFL
head team physicians felt a single ketorolac injection alleviated
50% to 75% of a player’s pain and lasted 1 to 2 days. Because of
this, most staff (24/27 [89%]) stated that they would give
ketorolac up to once a week during the season.31 In the survey
of AMSSM/AOSSM members, 50% of respondents believed that
ketorolac injection improved function, while 38.3% thought it
accelerated the return to activities.26 Each injection was
perceived to be efficacious for less than 24 hours.26
Corticosteroid injection treatment also appears effective. When
used in the treatment of hamstring strain in NFL players, 49
players (84.5%) missed no game time, 8 players missed 1 game,
and 1 player missed 2 games.13 Overall treatment of these
athletes still averaged 24 days (range, 6-65 days).13 When
considering corticosteroid injection for treatment of a variety of
injuries, Drakos et al7 reported that all players were able to
return to play at some time after their injection (mean, 10.4
days), with 55% of players not missing a single game. Athletes
injected for quadriceps strains missed an average of 4 games
(mean, 36.5 days), and those injected for hamstring strains
missed an average of 3 games (mean, 28 days).7
Adverse Effects of Injectable Ketorolac
and Corticosteroids in Athletes
Only 4 of the identified studies mentioned adverse events from
the use of game day injection treatment in athletes.7,13,26,31
Reports of adverse effects from game day ketorolac injection in
athletes are low. In the NFL, only 6 adverse events were
reported over a single season. These included 4 isolated muscle
injuries, 1 gastrointestinal disturbance, and 1 instance of nextday postinjection soreness. Several teams expressed concern
about psychological dependence by players, but this was not
studied further.31 AMSSM/AOSSM members reported local skin
reaction (5%), bleeding (2.9%), and kidney problems (1.9%) as
the most common adverse events, but the severity of these
events was not described. Of respondents, 88% reported no
adverse events.26 No minor or major adverse events were
reported with the use of game day corticosteroid injection,7,13
specifically, no infections, no major re-aggravation of hamstring
injury, and no muscle rupture.13

Discussion
The purpose of this systematic review is to evaluate the
utilization, efficacy, and adverse effects of injectable ketorolac
and corticosteroids in athletes. With no prospective studies
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regarding the use of these injectable medications in this patient
population, the report quality is low. All identified studies were
either retrospective reviews7,13 or physician surveys,5,26,28,31 and
the majority focused only on male professional football
players,7,13,28,31 with 1 study focusing on collegiate male football
players,5 and 1 considering all sports and both male and female
participants.26
Oral NSAID use is a mainstay of treating musculoskeletal
injuries in athletes. Oral NSAIDs such as ibuprofen and
naproxen are widely used by athletes. Ziltener et al36 surveyed
college athletes and found that 29% reported routinely taking
NSAIDs immediately prior to match play. That same group
found that NSAIDs were reportedly useful for some muscle
injuries but not others. Athletes reported improvement in
symptoms for injuries, such as contusions and delayed-onset
muscle soreness, but not strains.36
Ketorolac is currently the only Food and Drug
Administration (FDA)–approved injectable NSAID medication.
Since FDA approval in 1989, ketorolac has become a favored
medication for game day pain relief in athletes. The IM and
IV formulations have a more rapid onset of action than many
traditional oral NSAIDs, reaching therapeutic plasma levels in
less than 10 minutes.26 It is a highly charged compound with
99% of the compound bound to albumin in plasma.25 With
such rapid onset and a half-life of roughly 6.5 hours, coupled
with a low cost, it has ideal anti-inflammatory properties with
regard to pain management and cost. Also available in oral
(per os [PO]) and intranasal formulations, ketorolac has
shown good pain relief efficacy regardless of route of
administration.3 The absorption, onset of action, and duration
of effect between the injectable and PO forms are quite
similar. The excellent PO absorption stems partially due to
99% protein binding once absorbed via the gut.3,19 Onset to
analgesic effect of the IM formulation is approximately 30
minutes and between 30 and 60 minutes for PO. Both IM and
PO offer approximately 4 to 6 hours of pain relief. Even cost
has little variation between formulations. Interestingly, the
analgesic effect is capped at 10 mg, with studies showing no
additional benefit above that dosage. Based on the evidence
available, for athletes who require pain management on the
sideline, PO ketorolac would be justified over IM due to
equivocal bioavailability and efficacy, without the risk
associated with injections.
Emergency department data comparing IM ketorolac, PO
ibuprofen, and both IM/PO placebos for mild to moderate
musculoskeletal pain found that the analgesic effect was not
statistically different.32 The same study found no significant
difference in time to analgesic effect. Another double-blinded
study compared efficacy of varying doses for IM ketorolac for
moderate to severe pain in an emergency department setting
found no statistically significant improvement in pain scores
with doses above 10 mg of IM ketorolac.18 No studies were
found that specifically compared PO and IM ketorolac for
analgesic effect on muscular injuries.
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Ketorolac slows muscle healing by indiscriminate reversible
inhibition of COX-1 and COX-2.3,10 While short-term analgesia is
a desired effect and is not typically detrimental to overall
healing because of the reversible nature of the medication,
acute and chronic use of ketorolac can suppress the body’s
natural course of tissue repair and lead to poor healing.1 In
athletes, chronic ketorolac use may theoretically increase
thresholds for pain during rehabilitation, while at the same time
cause delayed healing and subsequently greater risk of reinjury
of suboptimally healed muscle. In rat models with induced
eccentric muscle contraction injuries, researchers have
repeatedly been able to prove, with statistical significance, that
injection with ketorolac leads to decreased torque generation in
the injured muscles. This reduction in strength was shown with
repeated consistency when testing was performed over the
course of both days and weeks.29
Side effects of ketorolac are similar to other NSAIDs that work
by inhibiting the COX pathway. Adverse effects include
dyspepsia, gastrointestinal bleeding/ulceration, renal
dysfunction, and reduction in platelet function and blood
clotting. Extended use of parenteral ketorolac at higher doses
increases the risk of gastrointestinal side effects (20%) and renal
impairment.8 NSAIDs should be avoided in individuals with
coexisting gastric disorders.24 Additionally, increasing the dose
of ketorolac beyond a daily maximum of 40 mg in adults does
not provide improved efficacy, but will increase the risk of
developing serious adverse events.14
NSAIDs should also be avoided in athletes with a history of
baseline renal disease. Healthy adults experience transient
decreases in renal blood flow and glomerular filtration rate
while on a salt-restricted diet.34 NSAID use in healthy
individuals who were renally stressed with dehydration,
exercise, and heat exposure demonstrated a small but
significant drop in glomerular filtration rate compared with
acetaminophen and placebo.11 This can be compared in the
setting of salt-depleted athletes while competing/participating in
sport.
Ketorolac decreases platelet aggregation and thromboxane
production, increasing the potential to cause bleeding.27 This is
an important consideration in contact/collision sports due to
risk of injury to the brain, liver, spleen, and kidneys. Systemic
side effects of ketorolac must be considered as well, including
headache, asthma, and a negative effect on fracture healing.
Mehallo et al16 identified practical management guidelines
through the basis of animal models and limited human studies.
Specifically, NSAIDs should be avoided in the treatment of
completed fractures, stress fractures at higher risk of nonunion,
or in the setting of chronic muscle injury.16 In experimental
animal models, COX-2 inhibitors have been shown to have less
gastrointestinal side effects compared with their other NSAID
counterparts. However, the same study also demonstrated
detriments to tissue-level repair. Specifically, they have been
shown to impair mechanical strength return after acute injury to
bone, ligament, and tendon.33
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Table 1. Recommendations from the NFL Physician Society task force on the use of ketorolac in the NFL that are more specific to
the NFL (and general sports medicine) patient population
1

Ketorolac should not be used prophylactically as a means of reducing anticipated pain either during or after
participation in NFL games or practices.

2

Ketorolac use should be limited to those players diagnosed with an injury or condition and listed on the teams’ latest
injury report or after a physician diagnosed injury or condition that occurs after the last injury report has been
submitted to the NFL prior to competition.

3

Ketorolac should be given in its oral preparation under typical circumstances, as it is recognized that the oral
preparation (1) has faster onset of action on the IM preparation, (2) has a duration of action that is equivalent
to the IM and IV forms, and (3) has a plasma concentration-time curve that is nearly identical to the IM and IV
preparations.

4

IM and IV injection of ketorolac should not be used except after an acute, game-related injury where significant
visceral or central nervous system bleeding is not expected and where other oral or IM pain medications are
inadequate or not tolerated. If IM or IV ketorolac is felt to be appropriate by the treating physician, the lowest
possible dose should be used.

IM, intramuscular; IV, intravenous; NFL, National Football League.

A task force appointed by the NFL Physician Society published
recommendations on the use of ketorolac in the NFL in 2012.15
There were 8 primary recommendations listed. Some of these
recommendations are common to the use of any NSAID
medication (in athletes and the general patient population): The
medication should only be administered under the direct
supervision and order of a team physician; it should be given in
the lowest effective dose; it should not be given with other
NSAIDs; and it should not be taken by players with a history of
allergic reaction to ketorolac or other NSAIDs, in a player with
renal compromise, or a player with a history of prior adverse
reaction to ketorolac or other NSAIDs. Recommendations more
specific to the use of ketorolac in NFL athletes are listed in
Table 1.
Contraindications to corticosteroid injections include injecting
near a localized infection, injecting at a fracture site, or injecting
areas at high risk for tendon rupture. Potential side effects
include postinjection pain flare, soft tissue and subcutaneous fat
atrophy, skin hypopigmentation, and, most significantly in the
athlete, tendon or ligament weakening or rupture.21 Of the listed
complications, excluding pain, skin atrophy (2.4%) and skin
hypopigmentation (0.8%) are the most frequently noted
complications. Fat atrophy and skin hypopigmentation are more
likely to occur with superficial injection sites, possibly due to
overinfiltration of medication into the subcutaneous tissues. Soft
tissue changes may occur anywhere from 6 to 12 weeks after
injection.12 There are numerous case reports of tendon rupture
after corticosteroid injection, with plantar fascia and Achilles
tendon the most commonly reported ruptures.20,21
Route of administration of medication is an important
consideration regardless of the material being used, as a
potential for adverse events exists during any injection
6

procedure. Infection, bleeding, and postinjection neuritis have
been reported. Complications can be prevented with strict
adherence to aseptic techniques and being familiar with the
local anatomy of the injection site.6 There are no prospective
studies reporting on adverse events from the use of IM
ketorolac in athletes.
Ethical Considerations
Being a physician in the world of athletics has unique ethical
challenges. Balancing the interests of athletes, coaches, families,
school administrators, team owners, and agents is often difficult.
The primary ethical issue that must be addressed is “first do no
harm.” As stated by Testoni et al,30 the use of injections is
controversial and poses an important ethical dilemma. Is it
ethical to assist someone in masking their pain simply so they
can compete in a sporting event when participation may lead to
even greater injury? Could delaying recovery of muscular
injuries with NSAIDs cause more harm than benefit?
Furthermore, the decision-making process for underaged
athletes in the high school or college setting may complicate the
situation as more individuals are involved. The use of local
anesthetic injections in athletes is not considered performanceenhancing22 and is not banned by WADA, and the use of
corticosteroids may be allowed through the TUE process.35
However, the use of these injections has its own set of possible
side effects and complications. The ultimate outcome of
reducing pain and maximizing performance are mixed. A
retrospective study conducted on professional rugby players in
Australia demonstrated that performance between players
injected and not injected with a local anesthetic was not
substantially different.23 The complexities of short-term gains for
an athlete who chooses to stay on the field by limiting pain and
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enabling maximum performance are enormous. Thus, it is
crucial for the team physician to work with the athlete to make
an informed decision.

Conclusion
The current systematic review reveals that pregame IM
ketorolac injections are commonly used by professional and
collegiate football team physicians with good efficacy and
limited side effects. The use of injectable ketorolac in this
patient population is declining. The incidence of game day
corticosteroid injection use by team physicians is unknown.
There is evidence that use of injectable corticosteroids may
lead to early return to play with no adverse events. Game day
injections of ketorolac and corticosteroids, and the use of oral
NSAIDs are common in sports medicine. Injection of ketorolac
and use of oral NSAIDs have potential to decrease pain and
inflammation in the setting of a musculoskeletal injury;
however, use of such medications carries risks for the athlete,
including gastrointestinal side effects, renal dysfunction,
bleeding, and delayed healing. Because oral NSAIDs have rapid
onset of action, similar duration of action and equal pain
relieving efficacy as IM ketorolac, the possible adverse effects
of the injection procedure can be avoided altogether by
utilizing oral preparations when pregame analgesia is desired.
Because of the recognized increased bleeding risk, the use of
NSAIDs should be handled carefully in the setting of collision
sports. Ethical concerns of when to use such medications may
prove difficult, as many medical and social factors may affect
one’s decision. Finally, with the continued, significant use of
pregame IM ketorolac for pain management at the collegiate
and professional levels, it is time for the sports medicine
community to prospectively study its use and report on both
the positive and the negative outcomes encountered.
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